Clinical Trial Update: PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC [Phase 3]

View source ↗

Summary

This clinical trial update describes an ongoing Phase 3 study evaluating PARP inhibitor or capecitabine in combination with PD-1 inhibitors as adjuvant therapy …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• PARP inhibitor (class) (PARP inhibitor)
• PD-1 inhibitor (class) (PD-1 inhibitor)

Snippet

Sponsor: Guangdong Provincial People's Hospital | Conditions: Triple-negative Breast Cancer | Phase 3 | Status: RECRUITING